Celladon Mydicar drug receives FDA fast track status
Mydicar is a genetically targeted enzyme replacement therapy designed to restore levels of SERCA2a, that regulates calcium cycling and contractility. The randomized double-blind placebo-controlled Phase 2 Calcium Up-regulation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.